{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:15:12Z","timestamp":1778926512245,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacl.2026.03.007","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:19:09Z","timestamp":1773458349000},"page":"887-897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guideline-based lipid-lowering therapy in acute coronary syndromes: A simulation of population-level impact on cardiovascular events and LDL-C goal achievement"],"prefix":"10.1016","volume":"20","author":[{"given":"Dylan L.","family":"Steen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9832-0904","authenticated-orcid":false,"given":"Irfan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Koumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaja","family":"Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-7675","authenticated-orcid":false,"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.03.007_bib1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jama.2022.0358","article-title":"Diagnosis and treatment of acute coronary syndromes: a review","volume":"327","author":"Bhatt","year":"2022","journal-title":"JAMA"},{"issue":"9753","key":"10.1016\/j.jacl.2026.03.007_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jacl.2026.03.007_bib3","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jacl.2026.03.007_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamacardio.2020.0882","article-title":"Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial","volume":"5","author":"Gencer","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"42","key":"10.1016\/j.jacl.2026.03.007_bib5","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.jacl.2026.03.007_bib6","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"10.1016\/j.jacl.2026.03.007_bib7","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.03.007_bib8","article-title":"Guideline on the management of dyslipidemia: a report of the American College of cardiology\/american heart association joint committee on clinical practice guidelines","author":"Blumentha","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.03.007_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2023.8646","article-title":"Low-density lipoprotein cholesterol levels in adults with coronary artery disease in the US, January 2015 to March 2020","volume":"330","author":"Aggarwal","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jacl.2026.03.007_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022198","article-title":"Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239 234 patients during 2005\u20132018 in the United States","volume":"11","author":"Steen","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.007_bib11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.clinthera.2017.03.001","article-title":"Use of lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in the Netherlands","volume":"39","author":"Kuiper","year":"2017","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.007_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013255","article-title":"Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines","volume":"7","author":"Steen","year":"2017","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.007_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamacardio.2019.0198","article-title":"Evaluation of mortality data from the Social Security Administration Death Master File for Clinical Research","volume":"4","author":"Navar","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"15","key":"10.1016\/j.jacl.2026.03.007_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016506","article-title":"Time-dependent cardiovascular treatment benefit model for lipid-lowering therapies","volume":"9","author":"Khan","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.jacl.2026.03.007_bib15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2026.03.007_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2019.06.005","article-title":"Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"216","author":"Cannon","year":"2019","journal-title":"Am Heart J"},{"issue":"40","key":"10.1016\/j.jacl.2026.03.007_bib17","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","article-title":"Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study","volume":"41","author":"Allahyari","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.03.007_bib18","unstructured":"Python Software Foundation. Python Language Reference, version 3.9. http:\/\/www.python.org. [Accessed February 2, 2026]."},{"issue":"16","key":"10.1016\/j.jacl.2026.03.007_bib19","first-page":"1408","article-title":"Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial","volume":"44","author":"Schwartz","year":"2023","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacl.2026.03.007_bib20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"issue":"10106","key":"10.1016\/j.jacl.2026.03.007_bib21","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jacl.2026.03.007_bib22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT Trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2026.03.007_bib23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jacl.2026.03.007_bib24","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jacl.2026.03.007_bib25","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.007_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","article-title":"Effect of alirocumab on mortality after acute coronary syndromes","volume":"140","author":"Steg","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacl.2026.03.007_bib27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.jacl.2026.03.007_bib28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"Circulation"},{"issue":"39","key":"10.1016\/j.jacl.2026.03.007_bib29","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur Heart J"},{"issue":"suppl\u00a01","key":"10.1016\/j.jacl.2026.03.007_bib30","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"38","key":"10.1016\/j.jacl.2026.03.007_bib31","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacl.2026.03.007_bib32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","article-title":"LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals","volume":"134","author":"Underberg","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jacl.2026.03.007_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13098-020-00559-7","article-title":"Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review","volume":"12","author":"Andreozzi","year":"2020","journal-title":"Diabetol Metab Syndr"},{"issue":"25","key":"10.1016\/j.jacl.2026.03.007_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011121","article-title":"Clinical inertia in the pharmacological management of hypertension: a systematic review and meta-analysis","volume":"97","author":"Milman","year":"2018","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.007_bib35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/clc.23988","article-title":"Addressing current challenges in optimization of lipid management following an ACS event: outcomes of the ACS EuroPath III initiative","volume":"46","author":"Catapano","year":"2023","journal-title":"Clin Cardiol"},{"issue":"suppl B","key":"10.1016\/j.jacl.2026.03.007_bib36","doi-asserted-by":"crossref","first-page":"B114","DOI":"10.1093\/eurheartjsupp\/suad086","article-title":"Acute coronary syndromes: hospital management of dyslipidaemia with proprotein convertase subtilisin\/kexin 9 inhibitors: time to act","volume":"25","author":"Musumeci","year":"2023","journal-title":"Eur Heart J Suppl"},{"issue":"12","key":"10.1016\/j.jacl.2026.03.007_bib37","first-page":"939","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.007_bib38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/eurheartj\/ehaa1008","article-title":"Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care","volume":"42","author":"Ray","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacl.2026.03.007_bib39","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.jacl.2026.03.007_bib40","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jacc.2023.08.019","article-title":"Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy","volume":"82","author":"Biccir\u00e8","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.jacl.2026.03.007_bib41","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.007_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jjcc.2019.08.002","article-title":"Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome","volume":"75","author":"Yano","year":"2020","journal-title":"J Cardiol"},{"issue":"22","key":"10.1016\/j.jacl.2026.03.007_bib43","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.03.007_bib44","unstructured":"EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction (EVOLVE-MI). ClinicalTrials.gov identifier: NCT05284747. Updated November 15, 2024. Accessed March 26, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05284747#study-overview."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:04:30Z","timestamp":1778925870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1933287426000747"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.007","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guideline-based lipid-lowering therapy in acute coronary syndromes: A simulation of population-level impact on cardiovascular events and LDL-C goal achievement","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}